Fulgent Genetics, Inc. FLGT
Medical Specialities · IPO 2016 · data as of November 13, 2026
Fulgent Genetics, Inc. (FLGT) is a healthcare company listed in the US with a market value of about $689M. In the twelve months to September 30, 2026 it had revenue of $330M and net income of -$91M, a net margin of -27.5%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -5% a year, a 5-year average ROIC of 5%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 69% below the current price.
About Fulgent Genetics
Fulgent Genetics is listed in the US and classified in medical specialities, IPO year 2016. Revenue went from $1M in 2014 to $323M in 2025, growth of about 65.3% a year. It was profitable in 3 of the last 10 years in our data. It spends 17% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $330M | $323M | $283M | $289M | $619M | $993M | $422M | $33M | $21M | $19M | $18M |
| Net income | -$91M | -$61M | -$43M | -$168M | $143M | $507M | $214M | -$411000 | -$6M | -$3M | -$5M |
| Free cash flow | -$1M | -$124M | -$19M | $5M | $235M | $515M | $105M | $4M | -$3M | -$2M | $617000 |
| EPS (diluted) | $-3.09 | $-1.97 | $-1.41 | $-5.63 | $4.63 | $16.38 | $8.91 | $-0.02 | $-0.31 | $-0.14 | $-0.39 |
| Net margin | -27.5% | -18.8% | -15.1% | -58.0% | 23.2% | 51.1% | 50.8% | -1.3% | -26.3% | -13.4% | -29.3% |
| ROIC | — | -7.2% | -5.5% | -13.4% | 10.7% | 42.8% | 38.2% | -0.4% | -7.4% | -4.2% | 1.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $25.00, 1% above the current price; targets range from $25.00 to $25.00; the consensus rating is “Hold”; expected EPS is $-1.70 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Fulgent Genetics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 69% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Fulgent Genetics pay a dividend?
Not currently.
Is Fulgent Genetics a good stock to buy?
We do not give buy or sell advice. Fulgent Genetics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.